Menú

| UNINET | Lista de correo: eusalud-l | Suscripciones | Club AUTOPSIAS | REA::EJAUTOPSY
Casos PAT::UNINET | BIOMED::UNINET | MisApuntes | ASION

Bitácora de admin

Micro to tele

Blog Micro to tele

About Micro to tele: I am a senior biomedical scientist working in a diagnostic histopathology lab in London, currently training for my Diploma of Expert Practice in Histological Dissection. I am passionate about molecular diagnostics, raising awareness of recognising pathological symptoms & processes and the importance of early detection. I also have a keen interest in oncogenesis, epigenetics and astronomy.

Blog Micro to tele: http://micro2tele.com/

El papel que juegan los Patólogos

El Colegio Americano de Patólogos CAP ha editado este póster para explicar cual es el papel que juegan los Patólogos en el sistema sanitario y la repercusión de su trabajo en la atención asistencial.

Role of Pathologist - CAP

Echa un vistazo al Tweet de @Pathologists: https://twitter.com/Pathologists/status/459748680552050688

__
Admin

Cervical Cancer Screening (PDQ®) - National Cancer Institute

Información del Instituto Nacional del Cancer de los EEUU en relación con el Despistaje del Carcinoma de Cuello Uterino. Información para pacientes sobre los Exámenes de detección del cáncer de cuello uterino (PDQ®).

___
Admin Eusalud

The history of pathology informatics

The history of pathology informatics: A global perspective

Seung Park, Anil V. Parwani, Raymond D. Aller, Lech Banach, Michael J. Becich, Stephan Borkenfeld, Alexis B. Carter, Bruce A. Friedman, Marcial Garcia Rojo, Andrew Georgiou, Gian Kayser, Klaus Kayser, Michael Legg, Christopher Naugler, Takashi Sawai, Hal Weiner, Dennis Winsten, and Liron Pantanowitz

Abstract: Pathology informatics has evolved to varying levels around the world. The history of pathology informatics in different countries is a tale with many dimensions. At first glance, it is the familiar story of individuals solving problems that arise in their clinical practice to enhance efficiency, better manage (e.g., digitize) laboratory information, as well as exploit emerging information technologies. Under the surface, however, lie powerful resource, regulatory, and societal forces that helped shape our discipline into what it is today. In this monograph, for the first time in the history of our discipline, we collectively perform a global review of the field of pathology informatics. In doing so, we illustrate how general far-reaching trends such as the advent of computers, the Internet and digital imaging have affected pathology informatics in the world at large. Major drivers in the field included the need for pathologists to comply with national standards for health information technology and telepathology applications to meet the scarcity of pathology services and trained people in certain countries. Following trials by a multitude of investigators, not all of them successful, it is apparent that innovation alone did not assure the success of many informatics tools and solutions. Common, ongoing barriers to the widespread adoption of informatics devices include poor information technology infrastructure in undeveloped areas, the cost of technology, and regulatory issues. This review offers a deeper understanding of how pathology informatics historically developed and provides insights into what the promising future might hold.

PMC: 3714902

J Pathol Inform. 2013; 4: 7. May 30, 2013. doi: 10.4103/2153-3539.112689

XII International Workshop of Lower Genital Tract Pathology

XII International Workshop of Lower Genital Tract Pathology. Roma 5 al 7 de Marzo del 2015

Welcome Message

Dear Colleagues,

Antonio Frega, Philip Davies and I, Cesare Gentili, are pleased to announce the XII Workshop of Lower Genital Tract Pathology which will be held in Rome from March 5th to 7th 2015.
These Workshops have a unique multidisciplinary nature covering all disciplines related to diseases of the lower genital tract.
The last Workshop was attended by over 500 participants from 39 countries and with 55 speakers of international renown who maintained the participants’ interest for the entire congress by delivering a challenging and comprehensive program. We have no doubt that the upcoming congress will be an even bigger success.
For 2015, we have made some changes to the program by introducing some innovative elements in order to make it a more dynamic workshop while still keeping a sharp focus on the new issues that are of interest to clinicians and scientific validity.
More time will be allowed for debates, particularly in the specialized sessions on topics of interest in daily practice. There will be four interactive sessions, two for gynaecologists and two for pathologists, that will be based on clinical cases presentations using slides and videos. In each specialisation, one session will be led by the speakers and the other by the participants who will present previously selected cases. And there will be the new Twitter style Sessions, an effective way to summarize the salient points of the day.
After the success of the “Free Communications” in the previous Workshop, we have decided to repeat it this year too. Prizes will be given to the best three communications during the plenary session. Moreover, the participants will have the opportunity to vote for their favourite speaker and prizes will be given to the best three.
The multidisciplinary nature of the Workshop will allow experts from different fields to follow the topics of common interest in the plenary session as having the opportunity to learn about the latest development in their own specialist areas. The program will have a logical progression without duplications or overlap.
As in previous Workshop, the XII edition will have lectures covering the latest issues in cervical cancer prevention, diagnosis and treatment, and it will have the most highly respected researchers and clinicians from Italy and the rest of the world.
Although the congress has an international character, the atmosphere is informal and simple, and you can spend some pleasant days in Rome with us enjoying the typical dishes of the evocative Roman restaurants.

We now look forward to welcoming you to the XII Workshop of Lower Genital Tract Pathology in Rome next year.

With our best regards,

The Course Coordinators

firme

Actualizaciones sobre las Neoplasias Vulvares Intraepiteliales (VIN) (Revisión)

An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis

M Carolina Reyes, Kumarasen Cooper

Abstract: There are two distinct types of vulvar intraepithelial neoplasia (VIN), which differ in their clinical presentation, aetiology, pathogenesis and histological/immunophenotypical features. One form driven by high-risk human papilloma virus infection usually occurs in young women and has been termed classic or usual VIN (uVIN). The other, not related to viral infection, occurs in postmenopausal women with chronic skin conditions such as lichen sclerosus and lichen simplex chronicus and is termed differentiated or simplex-type VIN. The latter is the precursor lesion of the most common type of squamous cell carcinoma (SCC) in the vulva, namely keratinizing SCC (representing 60% of cases). In contrast, uVIN usually gives rise to basaloid or warty SCC (40% of cases). The histological features of uVIN are similar to those of high grade lesions encountered in other lower anogenital tract sites (hyperchomatic nuclei with high nuclear to cytoplasmic ratios and increased mitotic activity). However, differentiated VIN has very subtle histopathological changes and often escapes diagnosis. Since uVIN is driven by high-risk human papilloma virus infections, p16 immunohistochemistry is diffusely positive in these lesions and is characterized with a high Ki-67 proliferation index. In contrast, differentiated or simplex-type VIN is consistently negative for p16 and the majority of the cases harbour TP53 mutations, correlating with p53 positivity by immunohistochemistry.

J Clin Pathol 2014;67:290-294 doi:10.1136/jclinpath-2013-202117

MANIFIESTO 2014: MÉDICOS POR EL DERECHO A VIVIR

#Manifiesto2014 Científicos por el derecho a vivir

Madrid, 25 de febrero de 2014

Querido compañero:

Como sabes, el Gobierno ha prometido reformar la ley del aborto en el sentido de dar una mayor protección a la vida prenatal.

Recientemente hemos solicitado la adhesión a esta carta-manifiesto a un gran número de médicos españoles, en la que manifestamos nuestro apoyo al Gobierno en el paso dado hacia una mayor protección de la vida prenatal y solicitamos mejoras para conseguir disminuir las cifras de aborto en España.

La respuesta ha sido enormemente satisfactoria, no solamente por parte de los médicos sino por parte de muchos otros profesionales de la Sanidad y científicos que nos han propuesto extender esta solicitud de adhesión a estos otros colectivos de profesionales.

Es por esto que nos dirigimos nuevamente a vosotros para haceros extensiva la invitación a suscribir a esta carta: si en los días previos no habéis podido firmarla por estar dirigida al colectivo médico, ya podéis adheriros y difundirla entre todos vuestros compañeros.

Esperamos poder contar con tu firma y mostrar así a la opinión pública que somos muchos los médicos y profesionales que queremos cuidar a nuestros pacientes y ofrecer todas las alternativas necesarias para que las mujeres gestantes puedan seguir adelante con sus embarazos, asegurando también que se respete el derecho a la vida de sus hijos.

Muchas gracias por tu apoyo.

José Ignacio Sánchez Méndez
Sonsoles Alonso Salvador
Mª Jesús López Rodríguez
Esteban Rodríguez Martín
José Manuel Tubío Echagüe
Gádor Joya Verde

Médicos especialistas en Pediatría, Ginecología y Obstetricia

AQUÍ PUEDE ADHERIRSE AL MANIFIESTO: http://derechoavivir.org/manifiesto2014/

I Encuentro Sudamericano del Virus Papiloma Humano

I Encuentro Sudamericano del Virus Papiloma Humano. Santiago de Chile 31 Marzo-2 Abril 2014

Catterina Ferreccio Readi

Estimados colegas y amigos:

Este es un momento importante en el campo de la investigación del Papiloma Virus Humano, cuyos resultados están traduciéndose herramientas el alto impacto en la salud pública; sin embargo, la incorporación de estos avances ha sido muy lenta en algunos de los países de nuestra Región.

Creemos que este I Encuentro Sudamericano del Virus Papiloma Humano, propiciará un necesario intercambio de nuevos conocimientos, experiencias y debate sobre el estado de la investigación del VPH, en nuestra región y las dificultades para implementar las necesarias innovaciones en este campo. La discusión sobre el impacto de las estrategias actuales de prevención y control del VPH, en nuestros países del cono sur, estimulará nuevas colaboraciones y fortalecerá las ya existentes.

I Encuentro Sudamericano del Virus Papiloma Humano, ofrecerá un programa científico dinámico, potenciando la interacción de profesionales desde la perspectiva de la clínica (Ginecología y Obstetricia, Infectología, Microbiología, Dermatología y Venereología, Oncología, Enfermedades Respiratorias, Patología), de la Epidemiología, Salud Pública, Economía de la Salud, hasta de las ciencias básicas (Biología, Genética).

Espero recibirlos, en Marzo de 2014 en Santiago de Chile y que puedan disfrutar de la belleza y hospitalidad que Chile les ofrece!.

¡ Nos vemos en Santiago ! URL: http://www.hpvchile2014.com/

Dra. Catterina Ferreccio Readi
Presidenta del Comité Organizador
 

15th World Congress for Cervical Pathology and Colposcoy

15th World Congress for Cervical Pathology and Colposcoy

| Español | Home | Contact us

One Mission, Five Continents: Sharing our Knowledge with the World

The 15th World Congress for Cervical Pathology and Colposcop (IFCPC 2014) will promote the best possible standards of Colposcopy around the world with the goal of guaranteeing that women everywhere receive excellent care. IFCPC will feature structured training sessions that will improve clinician competence, performance and patient outcomes through educational activities focused around the study, prevention, diagnosis, and management of HPV and genital tract diseases. By placing the latest research and techniques at the service of health care professionals on every continent, the congress seeks to bridge the gap between theory and practice.

The BSCCP and 32 National Societies represented by the IFCPC, this congress will provide the perfect forum for sharing international knowledge and experience, dealing with core issues in cervical pathology and colposcopy. Meet the best and brightest minds working in the field at IFCPC 2014.

URL: http://ifcpc2014.com/

REA VOL 11, NÚM. 2 (2013)

REVISTA ELECTRÓNICA DE AUTOPSIA

La REA/EJA se centra en la Autopsia Clínica y Forense y con ella en las mejoras en cuanto a calidad asistencial y pericial. En cada número se presentan artículos originales, artículos de revisión y comentarios de internet así como exposición de casos interesantes acompañados de magníficas ilustraciones. Cobertura abarca métodos técnicos y ayudas de diagnóstico.

Novedades sobre el Ca de cervix y ERB2; carta en Nature

Landscape of genomic alterations in cervical carcinomas

Akinyemi I. Ojesina, Lee Lichtenstein, Samuel S. Freeman, et al.

Cuidado con los resultados de p16 negativos en CIN-2

HPV Detection and p16INK4a Expression in Cervical Lesions. A Comparative Study

Jordi Genovés, Frances Alameda, Gemma Mancebo, Josep Maria Solé,

Abstract: p16INK4a expression in dysplastic cervical lesions is related to high-risk human papillomavirus (HR-HPV) infection. The immunohistochemical expression of this protein in these lesions allows an increase in diagnostic reproducibility in biopsies and the introduction of prognostic factors in low-grade lesions. Here, we studied the immunohistochemical expression of p16 in 86 dysplastic cervical lesions, 54 cervical intraepithelial neoplasms - grade 1 (CIN-I), 23 CIN-II, and 9 CIN-III. In addition, we performed HPV detection and genotyping. We detected HR-HPV in 19/54 CIN-I, 21/23 CIN-II and 9/9 CIN-III cases. p16 INK4a immunoreactivity was observed in 7/19 CIN-I HR-HPV–positive, 17/21 CIN-II HR-HPV–positive and all CIN-III cases. Immunoreactivity for p16 INK4a was found in 7/54 CIN-I and in 17/23 CIN-II cases. In the follow-up, we detected 3 p16-positive high-grade squamous epithelial lesions (HSIL: CIN-II and CIN-III) in the CIN-I/p16-negative group and 5 p16-positive HSIL cases in the CIN-II/p16-negative group. We conclude that p16 negativity in CIN-I and CIN-II biopsies does not always imply regression of the lesion and that the diagnosis of CIN-II should not be based solely on p16 results.

Human Pathology Full-length article (In Press Accepted Manuscript) doi:10.1016/j.humpath.2013.10.035

___
Admin Eusalud